Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 543

1.

Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.

van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B.

JAMA. 2002 Nov 20;288(19):2441-8.

PMID:
12435257
2.
3.

Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.

Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL; SPORTIF Investigators.

Am Heart J. 2006 Nov;152(5):967-73.

PMID:
17070169
4.

Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.

Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A, Christensen CB, Lip GY, Køber L, Torp-Pedersen C, Hansen ML.

J Am Coll Cardiol. 2013 Sep 10;62(11):981-9. doi: 10.1016/j.jacc.2013.05.029. Epub 2013 Jun 7.

5.

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.

Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM.

Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.

6.

Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis.

Blann AD, Skjøth F, Rasmussen LH, Larsen TB, Lip GY.

Thromb Haemost. 2015 Aug;114(2):403-9. doi: 10.1160/TH15-05-0383. Epub 2015 Jun 11.

PMID:
26062437
7.

Oral anticoagulants vs. aspirin for stroke prevention in patients with non-valvular atrial fibrillation: the verdict is in.

van Walraven C, Hart RG, Singer DE, Koudstaal PJ, Connolly S.

Card Electrophysiol Rev. 2003 Dec;7(4):374-8. Review.

PMID:
15071258
8.

Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review.

Lane DA, Raichand S, Moore D, Connock M, Fry-Smith A, Fitzmaurice DA; Steering Committee.

Health Technol Assess. 2013 Jul;17(30):1-188. doi: 10.3310/hta17300. Review.

10.

WITHDRAWN: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.

Segal JB, McNamara RL, Miller MR, Powe NR, Goodman SN, Robinson KA, Bass EB.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD001938. Review.

PMID:
17636690
11.

Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.

Segal JB, McNamara RL, Miller MR, Powe NR, Goodman SN, Robinson KA, Bass EB.

Cochrane Database Syst Rev. 2001;(1):CD001938. Review. Update in: Cochrane Database Syst Rev. 2006;(3):CD001938.

PMID:
11279741
12.

Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.

Steinberg BA, Kim S, Piccini JP, Fonarow GC, Lopes RD, Thomas L, Ezekowitz MD, Ansell J, Kowey P, Singer DE, Gersh B, Mahaffey KW, Hylek E, Go AS, Chang P, Peterson ED; ORBIT-AF Investigators and Patients.

Circulation. 2013 Aug 13;128(7):721-8. doi: 10.1161/CIRCULATIONAHA.113.002927. Epub 2013 Jul 16.

14.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
15.

Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients.

Lip GY, Lanitis T, Mardekian J, Kongnakorn T, Phatak H, Dorian P.

Stroke. 2015 Oct;46(10):2830-7. doi: 10.1161/STROKEAHA.115.009995. Epub 2015 Aug 27.

16.

Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study.

Nielsen PB, Larsen TB, Skjøth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY.

Circulation. 2015 Aug 11;132(6):517-25. doi: 10.1161/CIRCULATIONAHA.115.015735. Epub 2015 Jun 9. Erratum in: Circulation. 2017 Feb 14;135(7):e48.

17.

Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.

Connolly SJ, Eikelboom JW, Ng J, Hirsh J, Yusuf S, Pogue J, de Caterina R, Hohnloser S, Hart RG; ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators.

Ann Intern Med. 2011 Nov 1;155(9):579-86. doi: 10.7326/0003-4819-155-9-201111010-00004.

PMID:
22041946
18.

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.

Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A; SPORTIF Executive Steering Committee for the SPORTIF V Investigators.

JAMA. 2005 Feb 9;293(6):690-8.

PMID:
15701910
19.

Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis.

Zhang JT, Chen KP, Zhang S.

Medicine (Baltimore). 2015 Jan;94(4):e409. doi: 10.1097/MD.0000000000000409. Review.

20.

Effect of clopidogrel added to aspirin in patients with atrial fibrillation.

ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S.

N Engl J Med. 2009 May 14;360(20):2066-78. doi: 10.1056/NEJMoa0901301. Epub 2009 Mar 31.

Supplemental Content

Support Center